Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07195175 · ClinicalTrials.gov registry record · Phase 1
Study of MAR002 in Healthy Men
A Phase 1 study of Acromegaly, sponsored by Marea Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT07195175: Recruiting Phase 1 study of Acromegaly, sponsored by Marea Therapeutics.
NCT07195175 is a Phase 1 study of Acromegaly that is actively recruiting participants, run by Marea Therapeutics. The registered enrollment target is 45 participants, below the 98-participant average among 13 other Acromegaly trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07195175, a Phase 1 study of Acromegaly, is actively recruiting participants, sponsored by Marea Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men
Primary Outcome
To evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MAR002
Study Locations (1)
Arizona
- Marea Site - Tempe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-08-11 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
What NCT07195175 shows while recruiting
NCT07195175 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 98-participant average among 13 other Acromegaly trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Acromegaly appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07195175 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT07195175 about?
NCT07195175 is a clinical study titled "Study of MAR002 in Healthy Men". Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men
What is the current status of trial NCT07195175?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2025-08-11. Estimated completion is 2026-07.
What conditions does trial NCT07195175 study?
This clinical trial studies the following conditions: Acromegaly.
What interventions are being tested in trial NCT07195175?
The interventions under investigation include: Placebo (DRUG), MAR002 (DRUG).
Who is sponsoring clinical trial NCT07195175?
This trial is sponsored by Marea Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07195175 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acromegaly
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07195175's enrollment target sits among peer trials
45 10th of 13 higher than 4 of 13 other Acromegaly trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acromegaly trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
RECRUITING · Phase 3
-
Diet in the Management of Acromegaly
RECRUITING · NA
-
Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly
ACTIVE NOT RECRUITING
-
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI